Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Determination of allergenic potency of Juniperus oxycedrus and Cupressus arizonica extracts in HEP units
2020-005389-32Phase 2Active
- Sponsor
- Inmunotek
- Start
- Aug 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polymerized juniperus oxycedrus pollen extract and cupressus arizonica pollen in seasonal allergic rhinitis (SAR), allergic rhinoconjunctivitis (ARC), allergic asthma and 3 more, sponsored by Inmunotek. Primary endpoint: Skin wheal area response to allergen extracts vs histamine. Started Aug 2022; status: active.
02
Drugs
polymerized juniperus oxycedrus pollen extractcupressus arizonica pollen
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)allergic asthmapollinosisJuniperus oxycedrus allergy
Beyond the preview
Go deeper on 2020-005389-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005389-32.